View More Recent Stories
-
Organon (OGN) Announces FDA Acceptance of BLA for HLX14
-
Organon (OGN) Completes Acquisition of Dermavant
-
TD Cowen Reiterates Hold Rating on Organon & Co. (OGN)
-
Organon (OGN) Reports Primary Endpoint Met in Phase 3 Comparative Clinical Study of HLX11
-
Organon (OGN) enters merger agreement with Dermavant Sciences
-
Organon (OGN) to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA Cream, 1%
-
JPMorgan Downgrades Organon & Co. (OGN) to Underweight
-
3 ways to gain stock market exposure to the fertility theme
-
Organon (OGN) and Lilly (LLY) Expand Migraine Commercialization Agreement to 11 Additional Markets
-
Organon (OGN) Tops Q2 EPS by 4c ; Offers Guidance
-
These stocks offer you exposure to rising demand for fertility treatment – Barclays

